Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182058 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Palbociclib-induced severe hepatitis: A case study and literature review.
Can Liver J
November 2021
Division of Gastroenterology, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Palbociclib is a selective and reversible CDK4/6 inhibitor approved for patients presenting with HR+ HER2- locally advanced or metastatic breast cancer. Its adverse effect (AE) is mainly reported on the occurrence of leukopenia and fatigue. Even though palbociclib has an extensive hepatic metabolism, there are rare reports about significant liver toxicity.
View Article and Find Full Text PDFAryl hydrocarbon receptor blocks aging-induced senescence in the liver and fibroblast cells.
Aging (Albany NY)
May 2022
Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de Extremadura, Badajoz 06071, Spain.
Aging impairs organismal homeostasis leading to multiple pathologies. Yet, the mechanisms and molecular intermediates involved are largely unknown. Here, we report that aged aryl hydrocarbon receptor-null mice () had exacerbated cellular senescence and more liver progenitor cells.
View Article and Find Full Text PDFPalbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma.
J Formos Med Assoc
September 2021
Tissue Bank, Chang Gung Memorial Hospital, Tao-Yuan 33305, Taiwan; Graduate Institute of Health Industry Technology and Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Tao-Yuan 33303, Taiwan. Electronic address:
Background/purpose: Palbociclib is an FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitor that has been clinically proven to be effective in breast cancer. However, its use in oral cancer is not well researched. In this study, we investigated the inhibitory activity of palbociclib against oral squamous cell carcinoma (OSCC) cells and explored the mechanism of inhibition.
View Article and Find Full Text PDFPalbociclib-Induced Liver Failure.
Kans J Med
April 2020
Department of Internal Medicine, University of Kansas School of Medicine-Wichita, KS.
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
Mol Oncol
August 2017
Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor-positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are under active investigation. Here, we report the effects and a novel mechanism of action of palbociclib in HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!